Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Pandemic Influenza Vaccine (GSK1562902A) in Children
NCT00502593Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2007
- Primary completion
- Dec 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Adjupanrix in influenza (12 arms), sponsored by GSK. Primary endpoints: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease at Month 24, Number of Seroconverted Subjects Against 2 Strains of Influenza Disease at Month 24 and 7 more. Started Jul 2007; status: completed.
02
Drugs
Adjupanrix
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00502593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502593.